The application of phosphatidylinositol-3 kinase inhibitors, such as LY294002 and Wortmannin, has been shown to suppress the phosphorylation of key signaling proteins including Akt, FKHRL-1, and p70S6K, thereby markedly reducing the proliferation of multiple myeloma cells (26). The gene discussed is AKT1; the disease is plasma cell myeloma.